FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3100358566> ?p ?o ?g. }

• W3100358566 abstract "Background A previous phase 2 study in metastatic breast cancer demonstrated a statistically significant improvement in overall survival (OS) in patients treated with pelareorep (pela) in combination with paclitaxel (PTX) versus PTX alone. 1 Given that pela is an intravenously delivered immuno-oncolytic reovirus, we hypothesized that the OS benefit from pela + PTX may be attributed to an adaptive T cell response triggered by pela. To examine if pela can mediate the priming of an anti-tumor immune response, we are conducting together with the SOLTI group the AWARE-1 study (a window-of-opportunity study of pela in early breast cancer), which is currently enrolling and for which initial translational research results are presented. Methods AWARE-1 is a window-of-opportunity study to evaluate the safety and effect of pela ± atezolizumab on the tumor microenvironment (TME) in 38 women with early breast cancer. Patients are treated with pela on days 1, 2, 8, and 9, while atezolizumab is administered on day 3. Tumor biopsies are collected at diagnosis, day 3, and day ~21. Five cohorts will be examined: Cohort 1: HR+/HER2-neg (10 patients) receiving pelareorep + letrozole; Cohort 2: HR+/HER2-neg (10 patients) receiving pelareorep + letrozole + atezolizumab; Cohort 3: TNBC (6 patients) receiving pelareorep + atezolizumab; Cohort 4: HER2+/HR+ (6 patients) receiving pelareorep + trastuzumab + atezolizumab; Cohort 5: HER2+/HR- (6 patients) receiving pelareorep + trastuzumab + atezolizumab. The primary endpoint of the study is CelTIL score [2], a metric for quantifying the changes in tumor cellularity and infiltration of TILs, where an increase in CelTIL is associated with a favorable response to treatment. Tumor tissue is being examined for pela replication, and changes to the TME are being assessed by immunohistochemistry and T cell receptor sequencing (TCR-seq). Peripheral blood is also being examined by TCR-seq. Results Detailed TCR-seq results from peripheral blood and tumor tissue are presented for the ten-patients enrolled into Cohort 1 who received pela and letrozole. In tumor tissue, T cell clonality increased in day 21 biopsies relative to baseline biopsies, with similar increases in T cell fraction (the number of T cells) in the majority of patients. In general, most of the tissue-expanded T cell clones were also seen in the peripheral blood. Conclusions Overall, these preliminary data from cohort 1 of AWARE-1 demonstrate that pela mediates priming of a T cell-based immune response that occurs both systemically and within breast cancer tissue. Trial Registration NCT04102618 Ethics Approval This study was approved by the Spanish Health Authority, protocol number 2018-003345-42. References Bernstein V, et al. A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213. Breast Cancer Res Treat 2018;167(2):485-493. Nuciforo P, et al. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. Ann Oncol 2018;29(1):170-177." @default.
• W3100358566 created "2020-11-23" @default.
• W3100358566 creator A5003167480 @default.
• W3100358566 creator A5007727405 @default.
• W3100358566 creator A5009145670 @default.
• W3100358566 creator A5010152267 @default.
• W3100358566 creator A5015289835 @default.
• W3100358566 creator A5018922989 @default.
• W3100358566 creator A5020462811 @default.
• W3100358566 creator A5025842545 @default.
• W3100358566 creator A5027849907 @default.
• W3100358566 creator A5032293249 @default.
• W3100358566 creator A5034492596 @default.
• W3100358566 creator A5042084238 @default.
• W3100358566 creator A5042649658 @default.
• W3100358566 creator A5048416170 @default.
• W3100358566 creator A5053376821 @default.
• W3100358566 creator A5059406043 @default.
• W3100358566 creator A5061522111 @default.
• W3100358566 creator A5070297345 @default.
• W3100358566 creator A5075332457 @default.
• W3100358566 creator A5075755020 @default.
• W3100358566 creator A5077175788 @default.
• W3100358566 creator A5078521568 @default.
• W3100358566 creator A5078634728 @default.
• W3100358566 creator A5080122151 @default.
• W3100358566 creator A5081369976 @default.
• W3100358566 creator A5084680706 @default.
• W3100358566 creator A5084688598 @default.
• W3100358566 creator A5085017566 @default.
• W3100358566 creator A5089513581 @default.
• W3100358566 date "2020-11-01" @default.
• W3100358566 modified "2023-10-15" @default.
• W3100358566 title "806 Changes in T cell clonality in AWARE-1 study, a window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer" @default.
• W3100358566 doi "https://doi.org/10.1136/jitc-2020-sitc2020.0806" @default.
• W3100358566 hasPublicationYear "2020" @default.
• W3100358566 type Work @default.
• W3100358566 sameAs 3100358566 @default.
• W3100358566 citedByCount "0" @default.
• W3100358566 crossrefType "journal-article" @default.
• W3100358566 hasAuthorship W3100358566A5003167480 @default.
• W3100358566 hasAuthorship W3100358566A5007727405 @default.
• W3100358566 hasAuthorship W3100358566A5009145670 @default.
• W3100358566 hasAuthorship W3100358566A5010152267 @default.
• W3100358566 hasAuthorship W3100358566A5015289835 @default.
• W3100358566 hasAuthorship W3100358566A5018922989 @default.
• W3100358566 hasAuthorship W3100358566A5020462811 @default.
• W3100358566 hasAuthorship W3100358566A5025842545 @default.
• W3100358566 hasAuthorship W3100358566A5027849907 @default.
• W3100358566 hasAuthorship W3100358566A5032293249 @default.
• W3100358566 hasAuthorship W3100358566A5034492596 @default.
• W3100358566 hasAuthorship W3100358566A5042084238 @default.
• W3100358566 hasAuthorship W3100358566A5042649658 @default.
• W3100358566 hasAuthorship W3100358566A5048416170 @default.
• W3100358566 hasAuthorship W3100358566A5053376821 @default.
• W3100358566 hasAuthorship W3100358566A5059406043 @default.
• W3100358566 hasAuthorship W3100358566A5061522111 @default.
• W3100358566 hasAuthorship W3100358566A5070297345 @default.
• W3100358566 hasAuthorship W3100358566A5075332457 @default.
• W3100358566 hasAuthorship W3100358566A5075755020 @default.
• W3100358566 hasAuthorship W3100358566A5077175788 @default.
• W3100358566 hasAuthorship W3100358566A5078521568 @default.
• W3100358566 hasAuthorship W3100358566A5078634728 @default.
• W3100358566 hasAuthorship W3100358566A5080122151 @default.
• W3100358566 hasAuthorship W3100358566A5081369976 @default.
• W3100358566 hasAuthorship W3100358566A5084680706 @default.
• W3100358566 hasAuthorship W3100358566A5084688598 @default.
• W3100358566 hasAuthorship W3100358566A5085017566 @default.
• W3100358566 hasAuthorship W3100358566A5089513581 @default.
• W3100358566 hasBestOaLocation W31003585661 @default.
• W3100358566 hasConcept C121608353 @default.
• W3100358566 hasConcept C126322002 @default.
• W3100358566 hasConcept C143998085 @default.
• W3100358566 hasConcept C203092338 @default.
• W3100358566 hasConcept C2775949291 @default.
• W3100358566 hasConcept C2777176818 @default.
• W3100358566 hasConcept C2777701055 @default.
• W3100358566 hasConcept C2778812593 @default.
• W3100358566 hasConcept C2779786085 @default.
• W3100358566 hasConcept C2780057760 @default.
• W3100358566 hasConcept C530470458 @default.
• W3100358566 hasConcept C535046627 @default.
• W3100358566 hasConcept C71924100 @default.
• W3100358566 hasConcept C72563966 @default.
• W3100358566 hasConcept C82210918 @default.
• W3100358566 hasConceptScore W3100358566C121608353 @default.
• W3100358566 hasConceptScore W3100358566C126322002 @default.
• W3100358566 hasConceptScore W3100358566C143998085 @default.
• W3100358566 hasConceptScore W3100358566C203092338 @default.
• W3100358566 hasConceptScore W3100358566C2775949291 @default.
• W3100358566 hasConceptScore W3100358566C2777176818 @default.
• W3100358566 hasConceptScore W3100358566C2777701055 @default.
• W3100358566 hasConceptScore W3100358566C2778812593 @default.
• W3100358566 hasConceptScore W3100358566C2779786085 @default.
• W3100358566 hasConceptScore W3100358566C2780057760 @default.
• W3100358566 hasConceptScore W3100358566C530470458 @default.
• W3100358566 hasConceptScore W3100358566C535046627 @default.
• W3100358566 hasConceptScore W3100358566C71924100 @default.
• W3100358566 hasConceptScore W3100358566C72563966 @default.
• W3100358566 hasConceptScore W3100358566C82210918 @default.

• next